VALBIOTIS
28.5.2019 17:42:20 CEST | Business Wire | Press release
Regulatory News:
VALBIOTIS (FR0013254851 – ALVAL / PEA/SME eligible), a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the successful industrial production of VALEDIA® (active substance TOTUM-63), the most advanced product in the VALBIOTIS portfolio. This achievement is the result of a collaboration with the Pierre Fabre group, a world-renowned expert in the industrial production of plant-based active substances.
Since securing industrial property rights in Europe and the United States, VALBIOTIS has made another major breakthrough by demonstrating its capacity to produce VALEDIA® industrially, and in accordance with the regulations governing these two markets.
Sébastien Peltier, CEO of VALBIOTIS, comments: "The industrial production of VALEDIA ® has come at the best possible time for VALBIOTIS, after obtaining strong preclinical and clinical results and securing the industrial property rights, in the lead-up to the publication of our Phase IIA clinical results. This is an important milestone, thus completing our health claim application and supporting our negotiations with a partner company to market the product in 2021. This development confirms the sustainability of our project to market plant-based products which target the causal mechanisms of metabolic diseases. To achieve this, we are following the regulatory process for dietary supplements with a health claim, while maintaining almost pharmaceutical-grade development standards."
VALEDIA® will be the first of a new class of products, aiming to prevent and combat metabolic diseases.
Industrial batches for future studies
VALBIOTIS is currently developing VALEDIA® for two labels: prediabetes and hepatic steatosis. The results of the Phase IIA clinical trial for prediabetes are expected by 31 July, 2019. They will be followed in the second half of the year by the launch of the European Phase IIB clinical study (REVERSE-IT) and the Phase IIB study (PREVENT-IT) in North America. The data from these studies will be used to submit the application to European and North American regulatory authorities, for a health claim to reduce the risk of type 2 diabetes, with a view to marketing the product in 2021.
Murielle Cazaubiel, Director of Development and Medical Affairs at VALBIOTIS, comments: "The success of this industrial production means we can progress to the next stages of clinical development with complete confidence. The new production capacities established with the Pierre Fabre group will be used in our two upcoming confirmation studies. This collaboration has enabled VALBIOTIS to benefit from leading expertise in the production of plant-based active substances, from extraction to standardization, ensuring that these results can be reproduced with both large and small quantities. "
“In 2015, we put our expertise in extracting plant-based active substances at the service of VALBIOTIS and accompanied them in their development. We produce 3 plant extracts that make up VALEDIA ® at our Gaillac (Tarn) extraction site. Today, we are happy to accompany them in this industrial transposition by manufacturing the capsules on our Cahors (Gers) production site specialized in phytotherapy and aromatherapy,” adds François MACAREZ, Business Developer at Pierre Fabre Médicament.
About TOTUM-63, the active substance of VALEDIA®
Prediabetes is a growing public health issue worldwide that has been acknowledged by international organizations. Without appropriate management, 70% to 90% of prediabetic subjects will develop type 2 diabetes.
VALEDIA® intend to be be the first natural and clinically proven solution specifically designed for prediabetics. VALEDIA® contains the active substance TOTUM-63, a unique and patented combination of 5 plant extracts, with high potential to target the physiopathological mechanisms of type 2 diabetes.
The launch of VALEDIA® is planned for 2021, with a health claim for reducing the risk of type 2 diabetes.
TOTUM-63 has already been proven safe and effective in healthy human volunteers during a Phase I/II clinical study.
The results of the first international Phase IIA study are expected before 31 July 2019.
ABOUT VALBIOTIS
VALBIOTIS is a French Research & Development company committed to scientific innovation for preventing and combating metabolic diseases. Its products are made for major players in the health care sector. VALBIOTIS particularly focuses on solutions to prevent type 2 diabetes, NASH (nonalcoholic steatohepatitis), obesity and cardiovascular diseases.
VALBIOTIS was founded in La Rochelle in early 2014 and has formed numerous partnerships with top academic centers in France and abroad, including La Rochelle University, the CNRS and Clermont Auvergne University located in Clermont-Ferrand. These partnerships have enabled Valbiotis to benefit from strong financial leverage, particularly thanks to experts and technical partners who support its projects. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and an American office in Boston (MA).
VALBIOTIS is a member of the "BPI Excellence" network and received the "Innovative Company" status accorded by BPI France. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs by obtaining support from the European Regional Development Fund (ERDF). VALBIOTIS is a PEA-SME eligible company.
Find out more about VALBIOTIS: http://valbiotis.com/
Name: VALBIOTIS
ISIN code: FR0013254851
Mnemonic code: ALVAL
Disclaimer
This press release contains forward-looking statements about VALBIOTIS' objectives. VALBIOTIS considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections can be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and doubts, including those described in the VALBIOTIS core document, filed with the French Financial Markets Regulator (AMF) on 5 April 2017 (application number I.17-012), as well as in the 2017 annual financial report, filed with AMF on 3 April 2018. These documents are available on the Company's website (www.valbiotis.com ). VALBIOTIS does not accept any liability regarding the update or revision of these forward-looking statements. This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, VALBIOTIS' shares or securities in any country.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190528005507/en/
Contact:
VALBIOTIS CORPORATE COMMUNICATION Carole Rocher / Marc Delaunay +33 5 46 28 62 58 medias@valbiotis.com
FINANCIAL COMMUNICATION ACTIFIN Stéphane Ruiz +33 1 56 88 11 14 sruiz@actifin.fr
MEDIA RELATIONS MADIS PHILEO Guillaume De Chamisso +33 6 85 91 32 56 guillaume.dechamisso@madisphileo.com
UNITED STATES SOLEBURY TROUT Rebecca John / Patrick Till +1 646 378 2935 rjohn@troutgroup.com ptill@troutgroup.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ROSHN Group Expands Foreign Real Estate Ownership Opportunities Across Saudi Arabia22.9.2026 09:00:00 CEST | Press release
ROSHN Group, Saudi Arabia’s leading master developer and a PIF company, is supporting a new chapter for international participation in the Saudi real estate market, as the Kingdom’s regulations governing non-Saudi property ownership create new opportunities for eligible international buyers and investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922356820/en/ ROSHN Group offers world-class living and investment opportunities, including SEDRA Curated Collection in Riyadh (Photo: AETOSWire) Thousands of non-Saudi buyers have registered interest with ROSHN Group since the regulatory updates, reflecting the growth and diversification of the Kingdom’s real estate sector by attracting new sources of demand and investment, while complementing the continued delivery of homes and communities for Saudi citizens. For ROSHN Group, this creates an opportunity to broaden access to its growing portfolio while expanding housing sup
Regnology Research Maps Route From AI Pilots to Production in Regulatory Reporting22.9.2026 08:33:00 CEST | Press release
Global study of 276 practitioners across 22 countries defines the “Agentic Gap” and outlines how financial institutions can transition from experimentation to governed, high-impact deployment.Supporting analysis by Oliver Wyman finds reporting absorbs 1% to 3% of total bank expenditure, with a concentrated share of it addressable by agentic workflows. Regnology, a leader in regulatory, risk, tax and finance reporting technology, today published “The Agentic Gap: From Control to Intelligence in Regulatory Reporting”, accompanied by a video foreword from Chief Executive Officer Rob Mackay. The global study sets out where agentic AI can take on meaningful operational load today, and gives institutions a practical roadmap from isolated pilots into scaled production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921218912/en/ The research finds an industry already mobilizing. 87% of respondents are exploring, piloting or embe
Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 20281 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 203022.9.2026 07:30:00 CEST | Press release
Bureau Veritas (BOURSE:BVI): CAPITAL MARKETS DAY 2026 Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution. › 2024-2026 achievements:Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3; Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit; New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company; Driving growth and profitability: through Portfolio
OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development22.9.2026 07:00:00 CEST | Press release
New portfolio combines high-performance cell culture media, molecule-specific CQA optimization, and integrated CDMO capabilities to help biosimilar developers accelerate the path to analytical similarity and improve process economics. OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHO™ platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar process development. OPM-CHO, the company’s portfolio of chemically defined cell culture media for CHO-based biomanufacturing, has supported more than 390 molecules in clinical and commercial stages worldwide, including biosimilars. Across 35 side-by-side evaluations, OPM-CHO media delivered an average titer improvement of
H2SITE Secures €3.4 Million (NOK 39.1 million) in Enova Funding to Scale Onboard Ammonia-To-Power for Commercial Maritime Applications22.9.2026 06:00:00 CEST | Press release
The 700 kW system builds on H2SITE’s previous maritime deployments and is designed as a modular, replicable solution for auxiliary power onboard vessels H2SITE has secured €3.4 million (NOK 39.1 million) in funding from Enova for HydraNord Power, a project that will develop and validate a commercial-scale onboard ammonia-to-power system for the maritime sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921324898/en/ Enova is one of the Norwegian government's primary instruments for accelerating the country's climate and energy transition. Its primary responsibility is to manage the Climate and Energy Fund on behalf of the Norwegian government. For H2SITE, Enova’s support is a major milestone in the commercialisation of its onboard ammonia cracking technology, enabling the company to scale from proven maritime demonstrations to replicable commercial solutions for the global shipping industry. Led by H2SITE, HydraNord
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom